Sign in with Google. Opens in new tab
bearish
Biosimilar Battlefield: An Update
473 Views15 Feb 2018 15:24
Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- HSCI Index Rebalance Preview and Stock Connect (Sep 2025): Plenty of Recent IPOs Could Be Added
- NTT DC REIT IPO - Thoughts on Valuation
- KCC Corp: EB Issue of $625 Million To HD KSOE + KCC Corp and KCC Glass Share Swaps
- [Japan M&A] YAGEO Extends Shibaura TOB Limbo at FSA/METI/BOJ Request on FEFTA
- Taste Gourmet FY25: Strong Results, FY26 To See Decent Growth
Top Unpaywalled Insights
More »- Oversupply Meets Tepid Demand Weighing Down on Soybean Meal
- [IO Technicals 2025/26] Bearish Momentum Intensifies
- "The Data Bottleneck in Quant Finance — and How to Break It" With David Forino, CTO of Quanted
- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Short Selling Viability Assessment on Celltrion After KOSPI 200 Inclusion02 Mar 2018
- Celltrion's Mar 8 KOSPI 200 Inclusion Event Update27 Feb 2018
- The Two Weeks in NorthAsia@Smartkarma That Were: BOJ/N225, Buybacks, & Biosimilars25 Feb 2018
- Biosimilar Battlefield: An Update15 Feb 2018
- Biosimilar Battlefield: U.S. Humira Pushed to 202303 Oct 2017
- Celltrion Has Potential Manufacturing Headaches07 Sep 2017
x